Login to Your Account


After Denufosol Failure, Inspire Ripe to Buy or Be Bought

By Trista Morrison


Tuesday, January 4, 2011
Shares of Inspire Pharmaceuticals Inc. fell 58.7 percent Monday after the firm said cystic fibrosis drug denufosol failed to meet its primary and secondary endpoints in a Phase III trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription


»

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Privacy Policy | Terms of Use
 
Part of Thompson Media Group LLC

Free Ezine

Sign up for Perspectives FREE e-mail newsletter.

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.